An elderly woman looking off into the distance.
An elderly woman looking off into the distance.

Investor Relations

Investor Relations represents MorphoSys and its equity story to the financial market and supports the Company's overall strategic communication. Through active and transparent investor relations work, the aim is to enable investors to make an informed decision of the Company.

Latest News

11/20/2023

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Read more
Linked InTwitter
11/20/2023

Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Read more
Linked InTwitter
11/15/2023

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Read more
Linked InTwitter
View All

Corporate Presentations and Reports

Morphosys-pres_960x720-desk
Morphosys-pres_786x504-Mobile

Corporate Presentation

Overview of our business strategy, mid- to late-stage oncology pipeline, financials and investment thesis.  

READ MORE
AR DT with title
AR MB with title

Annual Report 2022

We offer insights into our company, our mission as well as our corporate and financial report, our clinical pipeline and much more.

Read More
NFR DT with title
NFR MB with title

Non-Financial Group Report 2022

We provide information on business ethics and compliance as well as social, employee and environmental issues.

Read More

Third Quarter 2023 Financial Results

Press Release
Press Release
Read Press Release
Presentation Icon
Presentation for webcast
pdf | 1.24 MB
Go to Webcast

Events & Conferences

05 Dec 2023

The JMP Securities Hematology and Oncology Summit (Virtual)

 

Our CEO, Jean-Paul Kress, M.D., will present the company during a Webcast.

Date: Tuesday, December 5
Time: 12.30pm ET

Access Webcast

11 Dec 2023

ASH 2023 Investor Event with Medical Experts

 

The event will highlight pelabresib’s potential in first-line myelofibrosis with a comprehensive overview of the Phase 3 MANIFEST-2 trial results, which will be presented during an oral presentation at ASH 2023 on Sunday December 10. There will be live presentations from and a Q&A opportunity with MorphoSys management and leading medical experts. 

Monday, December 11, 7:00 a.m. – 8:30 a.m. PST  (10:00 a.m. - 11:30 a.m. EST / 4:00 p.m. - 5:30 p.m. CET)

Webcast Presentation

10 Jan 2024

42nd Annual J.P. Morgan Healthcare Conference

 

Our CEO, Jean-Paul Kress, M.D., will present MorphoSys during a Webcast.

Date: Wednesday, January 10, 2024
Time: 3.00 - 3.40pm PST

Access Webcast

VIEW ALL EVENTS

INVESTOR INFORMATION

Financial Information

Financial Information

Take a closer look at our Financial Guidance 2023 and the Fundamentals of MorphoSys.

Read more

Annual General Meeting

The virtual Annual General Meeting 2023 of MorphoSys AG.

Read more
Stock

Stock Information

MorphoSys stock information in detail.

Read more

Corporate Governance

We believe that our commitment to high Corporate Governance standards will ultimately increase shareholder value.

Read more
clinical trials
Clinical trials

Our Understanding of Sustainability

We are conscious of the responsibility we share for present and future generations and see sustainable action as a prerequisite for long-term business success.

Read more

Publications

0/0

SEC Filings

Read more

Order form for publications and reports

Get Press Releases (Corporate News, Annual Reports, Quarterly Reports).
Read more

Investor Contact

JNE

DR. JULIA NEUGEBAUER

HEAD OF INVESTOR RELATIONS

Tel. +49 89 89927 179
Julia.Neugebauer@morphosys.com
https://www.linkedin.com/in/julia-neugebauer-48a048b2